Skip to content

Genentech shows off Phase 3 hemophilia A data

July 11, 2017

Positive Phase III Results For Genentech’s Emicizumab In Hemophilia A Published In The New England Journal of Medicine 

 HAVEN 1 showed emicizumab reduced bleed rate by 87 percent compared with on-demand bypassing agents 

– All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate by 79 percent compared to prior prophylactic bypassing agents 

– Data from HAVEN 1 in adults and adolescents and interim data from HAVEN 2 in children with hemophilia A with inhibitors are being presented today at the 26th International Society on Thrombosis and Haemostasis (ISTH) Congress 

– Data from both studies have been submitted to FDA and EMA for approval consideration 

http://bit.ly/2ud5Oh1

Advertisements

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: